Burlingame, Calif.-based Cala Health Inc., which is developing wearable therapies for chronic disease, completed a $50 million series C financing. The funds are earmarked for introducing the Cala Trio for patients with essential tremor and expanding the company's therapeutic pipeline. In addition, Stacy Enxing Seng will join Cala as an independent director and board chair.